Evgen Pharma PLC (LON:EVG) was down 10.1% on Friday . The company traded as low as GBX 19.50 ($0.25) and last traded at GBX 19.50 ($0.25). Approximately 133,971 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 207,445 shares. The stock had previously closed at GBX 21.70 ($0.28).
Separately, Northland Securities reiterated a “buy” rating on shares of Evgen Pharma in a research report on Wednesday, December 12th.
The stock has a market capitalization of $20.19 million and a price-to-earnings ratio of -6.80.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Featured Story: Cryptocurrencies
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.